THERAVECTYS is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Their first clinical studies will be in HIV/AIDS, using their lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates.
Funding Rounds (2) - $28.3MUpdate
Bâtiment Pasteur Biotop
28 rue du Docteur Roux